Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 2/20 | 0.34 |
| ▸ | PGK2 | P07205 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15883887 | 0.87 | IRAK4 (0.48) | IRAK4PDCD1LG2CD274MEN1CYP2C9 | |
| SCHEMBL12060888 | 0.80 | MEN1 (0.52) | IRAK4PDCD1LG2CD274MAPTMEN1 | |
| SCHEMBL6226578 | 0.75 | TSHR (0.55) | CYP2C9TSHRKDM4E | |
| SCHEMBL27656707 | 0.74 | NCF1 (0.50) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL11356775 | 0.74 | IRAK4 (0.33) | IRAK4ACHEBCHEFAAH | |
| SCHEMBL15944555 | 0.74 | PDCD1LG2 (0.46) | PDCD1LG2CD274MAPTMEN1KMT2A | |
| SCHEMBL786336 | 0.73 | PGK1 (0.39) | PGK1PGK2MAPTCYP2C9TSHR | |
| SCHEMBL522951 | 0.70 | GAA (0.37) | IRAK4PGK1PGK2TSHRGAA | |
| SCHEMBL9054451 | 0.69 | APLNR (0.30) | — | |
| SCHEMBL4273303 | 0.69 | PGK1 (0.41) | IRAK4PGK1PGK2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415742-A1 | METHOD FOR PRODUCING ALCOHOL COMPOUND AND CATALYST THEREFOR | Sumitomo Chemical Company, Limited (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120029195-A1 | METHOD FOR PRODUCING ALCOHOL COMPOUND AND CATALYST THEREFOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| US-6864334-B2 | Multi-dentate late transition metal catalyst complexes and polymerization methods using those complexes | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2005-03-08 | — | — | US | disclosed |
| US-20050004334-A1 | MULTI-DENTATE LATE TRANSITION METAL CATALYST COMPLEXES AND POLYMERIZATION METHODS USING THOSE COMPLEXES | BOFFA LISA SAUNDERS (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040254067-A1 | Multi-dentate late transition metal catalyst complexes and polymerization methods using those complexes | BOFFA LISA SAUNDERS (US) | 2004-12-16 | — | — | US | disclosed |
| US-6809058-B2 | CU, AG AND AU COMPLEXES HAVING A MULTIDENTATE NITROGEN-CONTAINING LIGAND, SUCH AS 2,2':6',2'-TERPYRIDINE, (2,6-BIS(1-PHENYLIMINO) ETHYL)PYRIDINE, 1,4,7-TRIAZACYCLONONANE, OR THEIR SUBSTITUTED DERIVATIVES. | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2004-10-26 | — | — | US | disclosed |
| US-20030069128-A1 | Multi-dentate late transition metal catalyst complexes and polymerization methods using those complexes | EXXONMOBIL RESEARCH & ENGINEERING COMPANY | 2003-04-10 | — | — | US | disclosed |
| WO-2003020778-A1 | MULTI-DENTATE LATE TRANSITION METAL CATALYST COMPLEXES AND POLYMERIZATION METHODS USING THOSE COMPLEXES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004334-A1 | MULTI-DENTATE LATE TRANSITION METAL CATALYST COMPLEXES AND POLYMERIZATION METHODS USING THOSE COMPLEXES | NOX3, CA3, KCNN4 | IRAK4 2593/4885PDCD1LG2 1102/4885CD274 1254/4885 |
| US-20120029195-A1 | METHOD FOR PRODUCING ALCOHOL COMPOUND AND CATALYST THEREFOR | ADH1A, ADH1C, ADH5 | IRAK4 4469/4885PDCD1LG2 3886/4885CD274 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.